No Data
Selected announcement | SenseTime completes organizational restructuring, focusing on core businesses such as generative AI; zijin mining group completes delivery of the Peru gold mine project.
In the first 11 months, yuexiu property had a cumulative contract sales of 101.02 billion yuan, a year-on-year decrease of approximately 24%; Fangzhou Jianke was included in the hang seng hong kong-listed biotech index constituent stocks.
Hong Kong stocks morning report on December 4: The situation in south korea causes a huge shock in asset prices, while the trends of china concept stocks show divergence.
① South Korea's President Yoon Suk-yeol suddenly launched an emergency martial law, but Congress resisted and voted to reject it. ② The USA's labor market shows subtle changes: the number of job vacancies rebounds. ③ The number of CEOs leaving their positions in the USA this year has reached a record high. ④ Yen arbitrage trading is thriving, and the Bank of Japan is reaching for the "interest rate knife." ⑤ The three major US stock indexes had mixed results, with the Nasdaq and the S&P 500 index continuing to set new closing highs, while the trend of china concept stocks showed divergence.
Luye Pharma Gets Marketing Go-Ahead for Lung Cancer Drug From Chinese Regulator
Luye Pharma Gains Approval for Cancer Drug Zepzelca
Luye Pharma (02186.HK): Zanbija (injection of rubi titin) has been approved for market launch in mainland china.
Green Leaf Pharmaceuticals (02186.HK) announced on December 3 that its innovative drug Zanbizai (Lubiteradine for Injection) has been included in the priority review and approval procedure and has received marketing approval from the China National Medical Products Administration. It is used to treat metastatic small cell lung cancer (SCLC) in adult patients progressing after platinum-based chemotherapy or post-chemotherapy. Zanbizai is a selective oncogene transcription suppressor that not only inhibits tumor gene transcription, leading to tumor cell death, but also regulates the tumor microenvironment to further enhance its anti-tumor effect. The product received approval in the USA in 2020.
Express News | Luye Pharma - Approval of Zepzelca (Lurbinectedin for Injection) for Marketing in Mainland China by Nmpa
No Data
